Document is current
Any future updates will be listed below
-
Authors
Chetty, Ashwin K.
Khunte, Mihir
Chen, Alissa S.
Jastreboff, Ania M.
Krumholz, Harlan M.
- License Information
-
More Information
Article History
Received: 15 August 2024
Accepted: 22 October 2024
First Online: 30 October 2024
Declarations:
:
: N/A.
: Chetty works as a contractor for Close Concerns, which publishes a paid information service to which diabetes technology, therapy, and digital health companies subscribe. A full listing is available online ( ).Khunte has no conflicts of interest to disclose.Dr. Chen is supported by NIH T32 AG019134 and the National Clinician Scholars Program.Dr. Jastreboff conducts multicenter trials with Eli Lilly, Novo Nordisk A/S, and Rhythm Pharmaceuticals; serves on scientific advisory boards for Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Eli Lilly, Intellihealth, Novo Nordisk A/S, Pfizer, Regeneron Pharmaceuticals, Scholar Rock, Structure Therapeutics, Terns Pharmaceuticals, WeightWatchers, and Zealand Pharma.; and receives institutional grant funding from the NIH/NIDDK (grant Nos. R01DK099039, R01DK117651, R01DK136623, R01DK134398).Dr. Krumholz has received options for Element Science and Identifeye and payments from F-Prime for advisory roles; being a cofounder and holding equity in Hugo Health, Refactor Health, and ENSIGHT-AI; and having research contracts through Yale University from Janssen, Kenvue, Novartis, and Pfizer.Dr. Lu received support from the Sentara Research Foundation, the National Heart, Lung, and Blood Institute (grant Nos. R01HL169954, R01HL169171), and the Patient-Centered Outcomes Research Institute (No. HM-2022C2-28354).
Free to read: This content has been made available to all.
